Episurf Medical received a Notice of Allowance from the USPTO for a new patent, entitled “Metatarsal implant,” which relates to the big toe implant that the company has developed. This is the first approval within this patent family.
“This patent gives us protection in the U.S. within the field of implants for the metatarsal bone of the toe. This relates to the Episealer MTP implant for the big toe that the company has developed, a product that is currently undergoing a review process at the US FDA. We are delighted to get this patent in place, as part of our preparations for U.S. market launch of our big toe implant,” said Katarina Flodström, Deputy CEO, Episurf Medical.
Since 2023, Episurf Medical has been implementing a strategic focus that brings increased growth in the U.S. market.
Episurf Medical received a Notice of Allowance from the USPTO for a new patent, entitled “Metatarsal implant,” which relates to the big toe implant that the company has developed. This is the first approval within this patent family.
“This patent gives us protection in the U.S. within the field of implants for the metatarsal bone of the toe....
Episurf Medical received a Notice of Allowance from the USPTO for a new patent, entitled “Metatarsal implant,” which relates to the big toe implant that the company has developed. This is the first approval within this patent family.
“This patent gives us protection in the U.S. within the field of implants for the metatarsal bone of the toe. This relates to the Episealer MTP implant for the big toe that the company has developed, a product that is currently undergoing a review process at the US FDA. We are delighted to get this patent in place, as part of our preparations for U.S. market launch of our big toe implant,” said Katarina Flodström, Deputy CEO, Episurf Medical.
Since 2023, Episurf Medical has been implementing a strategic focus that brings increased growth in the U.S. market.
Copy to clipboard 
